Roivant joins forces with Korea's iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs
→ Antibiotic resistance is a problem of epidemic proportions that should arguably entice a swarm of R&D dollars, but these drugs command relatively cheap prices …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
